Persistent Link:
http://hdl.handle.net/10150/614258
Title:
Use of Double Anaerobic Coverage and its Implications
Author:
Gomez, Eddie; Shinde, Gaurav; Patel, Niyat; Matthias, Kathyrn; Nix, David
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2013
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Specific Aims: Metronidazole and clindamycin can be prescribed for anaerobic infections; however, patients are periodically prescribed a second agent with duplicate anaerobic coverage. The purpose of this project was to evaluate the frequency, appropriateness, and potential consequences of combination therapy against anaerobic organisms in patients prescribed metronidazole or clindamycin. Methods: In this IRB approved project, adult patients who were prescribed either intravenous metronidazole or intravenous clindamycin with or without another agent with anaerobic coverage for at least 48 hours at an academic medical center between May 2010 and April 2012 were evaluated. Subjects were excluded if documented Clostridium difficile associated diarrhea within 14 days prior to intravenous metronidazole, if use of oral vancomycin within 14 days prior to intravenous metronidazole, or if presence of diarrhea with more than six unformed stools 48 hours prior to intravenous metronidazole. Data collected includes demographic information, site of infection, surgical interventions, antibiotic therapy prescribed, therapy outcomes, and reported adverse events. The odds ratio for combination anti-anaerobic therapy was calculated for metronidazole and clindamycin. The appropriateness of combination anaerobic coverage therapy was evaluated based on expert opinion and guideline statements. The frequency of potential complications such as adverse drug events, Clostridium difficile infection, other diarrheal illness and superinfections associated with enteric organisms within 30 days after starting anaerobic therapy will be reported Main Results: In Progress Conclusion: To be determined
Description:
Class of 2013 Abstract
Keywords:
anaerobic; implications; coverage
Advisor:
Matthias, Kathyrn; Nix, David

Full metadata record

DC FieldValue Language
dc.contributor.advisorMatthias, Kathyrnen
dc.contributor.advisorNix, Daviden
dc.contributor.authorGomez, Eddieen
dc.contributor.authorShinde, Gauraven
dc.contributor.authorPatel, Niyaten
dc.contributor.authorMatthias, Kathyrnen
dc.contributor.authorNix, Daviden
dc.date.accessioned2016-06-22T21:38:59Z-
dc.date.available2016-06-22T21:38:59Z-
dc.date.issued2013-
dc.identifier.urihttp://hdl.handle.net/10150/614258-
dc.descriptionClass of 2013 Abstracten
dc.description.abstractSpecific Aims: Metronidazole and clindamycin can be prescribed for anaerobic infections; however, patients are periodically prescribed a second agent with duplicate anaerobic coverage. The purpose of this project was to evaluate the frequency, appropriateness, and potential consequences of combination therapy against anaerobic organisms in patients prescribed metronidazole or clindamycin. Methods: In this IRB approved project, adult patients who were prescribed either intravenous metronidazole or intravenous clindamycin with or without another agent with anaerobic coverage for at least 48 hours at an academic medical center between May 2010 and April 2012 were evaluated. Subjects were excluded if documented Clostridium difficile associated diarrhea within 14 days prior to intravenous metronidazole, if use of oral vancomycin within 14 days prior to intravenous metronidazole, or if presence of diarrhea with more than six unformed stools 48 hours prior to intravenous metronidazole. Data collected includes demographic information, site of infection, surgical interventions, antibiotic therapy prescribed, therapy outcomes, and reported adverse events. The odds ratio for combination anti-anaerobic therapy was calculated for metronidazole and clindamycin. The appropriateness of combination anaerobic coverage therapy was evaluated based on expert opinion and guideline statements. The frequency of potential complications such as adverse drug events, Clostridium difficile infection, other diarrheal illness and superinfections associated with enteric organisms within 30 days after starting anaerobic therapy will be reported Main Results: In Progress Conclusion: To be determineden
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectanaerobicen
dc.subjectimplicationsen
dc.subjectcoverageen
dc.titleUse of Double Anaerobic Coverage and its Implicationsen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.